This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
5 Broker-Loved Stocks to Keep an Eye on Amid Trade Tensions
by Maharathi Basu
Investors should monitor stocks like Cardinal Health, DXC Technology, Cross Country Healthcare, Avnet and Asbury for high returns.
ResMed Stock Climbs 25.6% in a Year: What's Driving the Rally?
by Zacks Equity Research
RMD outperforms the industry and the S&P 500 composite due to its success with the cloud-connected AirSense platform.
SYK Stock Gains on Launch of Hands-Free Device: Sync Badge
by Zacks Equity Research
Stryker's Sunc Badge is a Hands-free, wearable communication device that will support care team members with fast and reliable collaboration. It is likely to help offset the ongoing nurse shortage.
VEEV Stock Falls Despite Latest Announcement to Enable AI Innovation
by Zacks Equity Research
Veeva Systems aims to enable advanced automation, including AI, for the life sciences industry via innovative technology and deep applications on the Veeva Vault Platform.
BSX Stock Set to Gain From the New Agreement to Acquire SoniVie Ltd.
by Zacks Equity Research
Boston Scientific inks a deal to acquire the remaining 90% stake in SoniVie Ltd.
TECH Joins Forces With Oxford Nanopore Technologies: Stock to Gain?
by Zacks Equity Research
Bio-Techne's Asuragen brand inks a partnership with Oxford Nanopore Technologies to launch research-use-only AmplideX Nanopore Carrier Plus Kit.
Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEV
Quest Diagnostics Stock Jumps 38% in a Year: What's Behind the Surge?
by Zacks Equity Research
DGX outperforms the industry and the S&P 500 composite's gain in the past year, driven by strong core performance and contributions from acquisitions.
Integra Q4 Earnings Beat Estimates, Revenues Rise Y/Y, Stock Up
by Zacks Equity Research
IART delivers better-than-expected earnings in the fourth quarter of 2024.
AMED Q4 Earnings and Revenues Miss, Margins Dip, Stock Rises
by Zacks Equity Research
Amedisys, for the fourth quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care.
SOLV Stock Down Despite Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Solventum's fourth-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.
TransMedics Stock Rises as Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
TMDX's fourth-quarter earnings depict strength in the company's net product revenues and services revenues. A rise in operating income bodes well for the stock.
OPK Stock Gains Following Q4 Earnings Beat, Gross Margin Expands
by Zacks Equity Research
The strength in OPKO Health's transfer of intellectual property and other revenues boosts its overall fourth-quarter 2024 performance despite lower RAYALDEE sales.
Growing Thrombectomy Business Supports PEN Stock, Macro Issues Ail
by Zacks Equity Research
Penumbra is still in the early stages of its journey to bring the company's proprietary thrombectomy technologies to patients in the United States and around internationally.
Alcon Stock Gains From Innovation Despite Macroeconomic Troubles
by Zacks Equity Research
Within Vision Care, ALC is registering solid growth, banking on strong sales of its contact lenses and ocular health products.
Teleflex Stock Rises on Q4 Earnings Beat, Gross Margin Crashes
by Zacks Equity Research
TFX benefits from a diversified product portfolio in the fourth quarter of 2024, with strength in the Surgical and Interventional segments.
Is it Apt to Retain Omnicell Stock in Your Portfolio Now?
by Zacks Equity Research
OMCL stays on investors' radar due to its impressive long-term growth initiative.
Chemed Q4 Earnings & Revenues Top, Stock Climbs, Margins Contract
by Zacks Equity Research
CHE's earnings and revenues beat estimates in the fourth quarter of 2024.
Is PAHC Stock a Smart Addition to Your Portfolio Right Now?
by Zacks Equity Research
Phibro's robust performance in the Animal Health business and prospects in the emerging markets are highly encouraging.
XRAY Q4 Earnings & Revenues Miss Estimates, Gross Margin Down
by Zacks Equity Research
DENTSPLY SIRONA's fourth-quarter results showcase dismal segmental performance with declining adjusted operating income.
AVNS Stock Gains Post Q4 Earnings & Revenue Beat, Margins Contract
by Zacks Equity Research
Strength in Avanos' Digestive Health segment drives its fourth-quarter 2024 performance despite global macroeconomic challenges.
TNDM Stock Falls in Aftermarket Following Q4 Earnings and Revenue Miss
by Zacks Equity Research
Tandem Diabetes' Q4 top and bottom lines lag their respective estimate. However, the company experiences strong sales growth both in and outside the United States.
EYE Q4 Loss Narrower Than Expected, Margins Rise, Stock Surges
by Zacks Equity Research
Continued strength in Managed Care aids National Vision's fourth-quarter 2024 performance.
Zacks.com featured highlights Prairie Operating, Intuit and Cardinal Health
by Zacks Equity Research
Prairie Operating, Intuit and Cardinal Health have been highlighted in this Screen of The Week article.
Watch These 3 Stocks for Solid Earnings Acceleration
by Tirthankar Chakraborty
Prairie Operating, Intuit and Cardinal Health are exhibiting strong earnings acceleration.